CU24665B1 - Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden - Google Patents

Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden

Info

Publication number
CU24665B1
CU24665B1 CU2020000081A CU20200081A CU24665B1 CU 24665 B1 CU24665 B1 CU 24665B1 CU 2020000081 A CU2020000081 A CU 2020000081A CU 20200081 A CU20200081 A CU 20200081A CU 24665 B1 CU24665 B1 CU 24665B1
Authority
CU
Cuba
Prior art keywords
chimeric protein
protein
receptor
binding domain
compositions
Prior art date
Application number
CU2020000081A
Other languages
English (en)
Spanish (es)
Other versions
CU20200081A7 (es
Inventor
Ávila Marta Ayala
Romero Mónica Bequet
Rico Ania Cabrales
Santiago Glay Chinea
Roche Diamilé González
Nieto Gerardo Enrique Guillen
Galindo Vivian Huerta
Pérez Enrique Iglesias
Fernández Miladys Limonta
Perera Gabriel Jesús Marquez
Dunn Alejandro Miguel Martín
Lasa Alexis Musacchio
Vazquez Eulogio Pimentel
Dorantes Gertrudis Rojas
MILIAN Héctor SANTANA
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000081A priority Critical patent/CU24665B1/es
Priority to CN202180088951.7A priority patent/CN116802194A/zh
Priority to US18/035,254 priority patent/US20230405106A1/en
Priority to CA3197024A priority patent/CA3197024A1/en
Priority to MX2023005211A priority patent/MX2023005211A/es
Priority to JP2023527114A priority patent/JP2023548205A/ja
Priority to AU2021373188A priority patent/AU2021373188A1/en
Priority to EP21834711.0A priority patent/EP4242222A1/en
Priority to PCT/CU2021/050010 priority patent/WO2022096039A1/es
Priority to ARP210103065A priority patent/AR123998A1/es
Publication of CU20200081A7 publication Critical patent/CU20200081A7/es
Priority to CONC2023/0004963A priority patent/CO2023004963A2/es
Priority to ZA2023/04779A priority patent/ZA202304779B/en
Publication of CU24665B1 publication Critical patent/CU24665B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CU2020000081A 2020-11-04 2020-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden CU24665B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2020000081A CU24665B1 (es) 2020-11-04 2020-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
JP2023527114A JP2023548205A (ja) 2020-11-04 2021-11-03 コロナウイルススパイクタンパク質の受容体結合ドメインを含むキメラタンパク質及びその組成物
US18/035,254 US20230405106A1 (en) 2020-11-04 2021-11-03 Chimeric protein comprising the receptor binding domain of the corona virus spike protein and compositions comprising them
CA3197024A CA3197024A1 (en) 2020-11-04 2021-11-03 Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions thereof
MX2023005211A MX2023005211A (es) 2020-11-04 2021-11-03 Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden.
CN202180088951.7A CN116802194A (zh) 2020-11-04 2021-11-03 包含冠状病毒刺突蛋白的受体结合结构域的嵌合蛋白以及包含其的组合物
AU2021373188A AU2021373188A1 (en) 2020-11-04 2021-11-03 Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising them
EP21834711.0A EP4242222A1 (en) 2020-11-04 2021-11-03 Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising them
PCT/CU2021/050010 WO2022096039A1 (es) 2020-11-04 2021-11-03 Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden
ARP210103065A AR123998A1 (es) 2020-11-04 2021-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
CONC2023/0004963A CO2023004963A2 (es) 2020-11-04 2023-04-20 Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden
ZA2023/04779A ZA202304779B (en) 2020-11-04 2023-04-25 Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000081A CU24665B1 (es) 2020-11-04 2020-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden

Publications (2)

Publication Number Publication Date
CU20200081A7 CU20200081A7 (es) 2022-06-06
CU24665B1 true CU24665B1 (es) 2023-06-13

Family

ID=79164940

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000081A CU24665B1 (es) 2020-11-04 2020-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden

Country Status (12)

Country Link
US (1) US20230405106A1 (enExample)
EP (1) EP4242222A1 (enExample)
JP (1) JP2023548205A (enExample)
CN (1) CN116802194A (enExample)
AR (1) AR123998A1 (enExample)
AU (1) AU2021373188A1 (enExample)
CA (1) CA3197024A1 (enExample)
CO (1) CO2023004963A2 (enExample)
CU (1) CU24665B1 (enExample)
MX (1) MX2023005211A (enExample)
WO (1) WO2022096039A1 (enExample)
ZA (1) ZA202304779B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7887978B2 (ja) * 2022-05-23 2026-07-10 バクスディグム カンパニー，リミティド ウイルスヌクレオカプシドを用いた結晶性タンパク質ベースの標的タンパク質融合自己組織化ナノ粒子製造プラットフォーム
KR102617592B1 (ko) * 2022-05-23 2023-12-29 주식회사 백스다임 바이러스 뉴클레오캡시드를 이용한 오량체형 독소 단백질 기반 목적 단백질 융합 오량체 제조 플랫폼

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗
CN111366734B (zh) * 2020-03-20 2021-07-13 广州市康润生物科技有限公司 双指标筛选新冠病毒及预判重型肺炎的方法
CN111620952A (zh) * 2020-06-17 2020-09-04 苏州米迪生物技术有限公司 基于嵌合型病毒样颗粒的新型冠状病毒疫苗
CN111676248A (zh) * 2020-07-02 2020-09-18 军事科学院军事医学研究院军事兽医研究所 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建

Also Published As

Publication number Publication date
JP2023548205A (ja) 2023-11-15
ZA202304779B (en) 2024-09-25
CO2023004963A2 (es) 2023-06-20
CA3197024A1 (en) 2022-05-12
CU20200081A7 (es) 2022-06-06
AU2021373188A1 (en) 2023-06-01
CN116802194A (zh) 2023-09-22
AR123998A1 (es) 2023-02-01
US20230405106A1 (en) 2023-12-21
WO2022096039A1 (es) 2022-05-12
EP4242222A1 (en) 2023-09-13
AU2021373188A9 (en) 2024-10-10
MX2023005211A (es) 2023-05-16

Similar Documents

Publication Publication Date Title
CO2022015415A2 (es) Aplicación antiviral de análogo de nucleósido o formulación combinada que contiene análogo de nucleósido
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CO2023004963A2 (es) Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden
BR112012018529A2 (pt) inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
CO6390077A2 (es) Inhibidores de hacv ns5a
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
CL2008002995A1 (es) Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih.
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
NI200700043A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan.
EA201791776A1 (ru) Замещенные циклофаны для использования при лечении инфекции вгс
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CR20210482A (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
UY31685A (es) Compuestos antivirales, composiciones y metodos para usarlos
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
CO2022008701A2 (es) Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza
ECSP22081150A (es) Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica